Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Notice of General Meeting 2019

March 13, 2019August 16, 2022 Kerry Rowe

Notice of General Meeting 2019

2019

Post navigation

Prana receives Orphan Designation for PBT434 for treatment of MSA

Prana receives A$3.3 million R&D Tax Incentive

Related Posts

Annual Report Filed on Form 20-F with SEC

September 7, 2017August 16, 2022

Alterity presents at Finance News Network investor event

December 2, 2020August 16, 2022

The Lancet Neurology publishes Prana’s Huntington’s Disease Trial

November 18, 2014August 16, 2022

Recent Posts

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson’s Disease and Movement Disorders
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
XBRL 30 June 2022 filed with the SEC
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065